Nemiralisib - GlaxoSmithKline

Drug Profile

Nemiralisib - GlaxoSmithKline

Alternative Names: [14C]-GSK2269557; GSK 2269557; GSK 2269557 ELLIPTA DPI

Latest Information Update: 23 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GlaxoSmithKline
  • Class Antiasthmatics; Indazoles; Indoles; Oxazoles; Piperazines; Small molecules
  • Mechanism of Action Phosphatidylinositol 3 kinase delta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Asthma; Chronic obstructive pulmonary disease; Immunodeficiency disorders

Most Recent Events

  • 03 Mar 2018 GlaxoSmithKline completes a phase I pharmacokinetics trial in healthy volunteers in USA (Inhalation) (NCT03398421)
  • 17 Jan 2018 GlaxoSmithKline initiates enrolment in a phase I pharmacokinetics trial in healthy volunteers in USA (Inhalation) (NCT03398421)
  • 16 Jan 2018 GlaxoSmithKline plans a phase I trial for Chronic obstructive pulmonary disease (NCT03398421)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top